The CECR2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the CECR2 gene in the human Raji B?lymphocyte background. This loss?of?function model leverages a heterogeneous pool of edited cells to abrogate CECR2 protein expression, enabling studies of chromatin remodeling and transcriptional regulation without the confounding influence of monoclonal selection artifacts. The polyclonal format preserves the cellular diversity inherent to the Raji line while providing a robust tool for functional genomics and epigenetic drug screening.
The Raji host cell line was derived from a Burkitt’s lymphoma patient and represents a well-characterized lymphoblastoid model of mature B cells. These cells constitutively express surface immunoglobulins and major histocompatibility complex molecules, retaining key features of antigen presentation, immunoglobulin production, and immune surveillance. Their transformed nature and rapid proliferation make them a widely adopted system for investigating B?cell malignancies and evaluating epigenetic therapies.
CECR2 encodes a core component of the CERF (CECR2?SMARCA1) chromatin?remodeling complex that couples histone acetylation to ATP?dependent nucleosome remodeling. CECR2 directly interacts with SMARCA1, EP300 histone acetyltransferase, and class I/II HDACs to regulate chromatin accessibility at target loci. Its activity is modulated by upstream signals including retinoic acid, PAX6, and SOX2, and it orchestrates transcriptional programs by controlling HOX gene clusters, neural crest specifiers, and cell?cycle regulators. Thus, CECR2 serves as a critical node linking extracellular cues to histone acetylation dynamics and developmental gene expression.
In the context of Raji B cells, CECR2 knockout is expected to perturb the CERF?dependent chromatin landscape, potentially altering the expression of genes governing B?cell proliferation, differentiation, and tumorigenesis. Given the putative tumor?suppressor role of CECR2 in certain cancers, this knockout model offers a platform to dissect its function in lymphoid malignancies. Dysregulation of histone acetylation and chromatin structure is a hallmark of Burkitt’s lymphoma, and CECR2 loss may sensitize cells to HDAC inhibitors, providing a rationale for mechanism?based drug testing.
This polyclonal knockout cell population is suited for a wide array of experimental applications, including elucidation of CERF complex function in hematopoietic cells, dissection of retinoic acid signaling in lymphoma, and transcriptome?wide analysis of chromatin?deregulated gene networks via RNA?seq. Typical assays include western blotting for CECR2 and target proteins, RT?qPCR of HOX and cell?cycle genes, ChIP?qPCR for histone H3 acetylation, flow cytometry for B?cell surface markers, and cell proliferation or HDAC?inhibitor sensitivity screens. For additional details or technical inquiries, please contact Ascent Research.
